CVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' Bankruptcy

Watchdoq May 13, 2025
(MedPage Today) -- Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss. (New York Times)
Transmasculine...

Read Full Article